QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-aclaris-therapeutics

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Neutral.

 hc-wainwright--co-reiterates-neutral-on-aclaris-therapeutics

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Neutral.

 aclaris-therapeutics-sells-olumiant-royalties-and-milestones-to-omers-life-sciences-for-up-to-315m

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 M...

 aclaris-therapeutics-q1-eps-024-beats-029-estimate-sales-240m-beat-137m-estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of ...

 lumen-technologies-and-2-other-stocks-under-2-insiders-are-buying

The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confi...

 aclaris-therapeutics-ati-1777-faces-uphill-battle-in-atopic-dermatitis-treatment-landscape-analyst-downgrades

HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, comm...

 why-commscope-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal L...

 why-coherus-biosciences-shares-are-trading-higher-by-22-here-are-20-stocks-moving-premarket

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announc...

 hc-wainwright--co-downgrades-aclaris-therapeutics-to-neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Buy to Neutral.

 why-is-dermatology-focused-aclaris-therapeutics-stock-trading-higher-today

Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION